Doi:10.1016/j.jalz.2009.05.027

Alzheimer's Imaging Consortium IC-P: Poster Presentations Background: Rosiglitazone, a peroxisome proliferator-activated receptor copy. Because of their high iron content, plaques typically appear as hypo- [gamma] (PPAR[gamma]) agonist, has an anti-inflammatory effect in the intense spots on T2-weighted scans. One of the challenges in imaging brain, decreasing interleukin-1[beta] concentrations in hippocampus and re- plaques is to achieve high-enough resolution and contrast to detect these storing the age-related deficit in long-term potentiation. It also attenuates 50-mm large lesions. While most high-field systems can reach high resolu- learning and memory deficits in a mouse model of Alzheimer's disease. Ev- tion, the lack of contrast between the plaques and the parenchyma often idence suggests that activation of microglia and astrocytes contribute to age- impedes their detection. Methods: Transgenic mice over-expressing muta- related neuroinflammatory changes. In this study, relaxometry measure- tions of the human genes responsible for familial forms of AD were stud- ments were assessed in hippocampus of young and aged rats because there ied. A total of eight APP/PS1 mice and seven wild-type mice were used for have been recent reports in the literature linking spin-lattice (T1) and spin- the in vivo study. The mice were injected in the lateral ventricles with spin (T2) relaxation times to astrocytic activation and microglial activation a non-specific gadolinium(Gd)-based contrast agent (CA). Within 6 hours respectively. Methods: Male Wistar rats aged 3 and 18 months (n ¼ 5-6 after injections, the animals were imaged in a 7 T Siemens system (Syngo per group) were treated either with 3 mg/day rosiglitazone maleate or MR VB15) using a 3D turbo spin-echo sequence (resolution ¼ with vehicle only for 56 days and MR images obtained under anesthesia 503503200 mm, scan time ¼ 2.5 hours). A total of six APP mice were using a 7-Tesla MRI scanner (Bruker) with slices selected to give optimal used for the ex vivo study where the extracted brains were fixed and stained regions of interest in dorsal hippocampus (Fig. 1). Images were acquired with a Gd CA for at least 24 hours, then imaged (3D FLASH gradient-echo using rapid acquisition with relaxation enhancement (RARE) and echo- sequence, resolution ¼ 653653200 mm and scan time ¼ 1 hour, or reso- train multi-slice-multi-echo (MSME) sequences, from which T1 and T2 lution ¼ 23323390 mm and scan time ¼ 12 hours). Results: There was maps were generated, respectively; and a fast imaging with steady-state a continuous diffusion of the CA into the parenchyma for up to 40 min precession (FISP) protocol, from which both T1 and T2 maps were gener- after injection, until it reached a plateau and remained in the brain for at ated. Data from manually-selected regions of interest were analyzed using least 5 hours. The images showed that prior to injection of CA, no plaques software scripts in IDL language (ITTVIS). One- or two-way analyses of were detectable in the cortex or hippocampus, whereas some were clearly variance (ANOVA) with Fischer's post-test were used to statistically assess visible after injection of CA. The ex vivo results showed that 50-mm large the data. Tissue from the animals was examined for markers of astrogliosis plaques could be detected after staining with the CA. However, individual and microglial activation. Results: T1 in hippocampus and cortex (p < plaques were only well-defined at high resolution, enabling quantification 0.01, Fig. 2) were significantly increased with age whilst T2 in hippocam- of the plaque load which was about 10% in the cortex. Conclusions: This pus (p < 0.05) and cortex (p < 0.01, Fig. 3) were significantly decreased study shows that amyloid plaques can be detected both in vivo and ex vivo with age. Treatment with rosiglitazone significantly attenuated the age-re- using a non-specific Gd-contrast agent. The level of detail achieved should lated T1 increase in both regions (p < 0.05, Fig. 2) and it increased T2 be sufficient for pharmacology studies.
relaxation time in hippocampus of aged, but not young rats (p < 0.05,Fig. 3). Conclusions: The data demonstrate an age-related increase in MEMORY LOSS IN YOUNG APPSWE/PS1DE9 MICE T1 in hippocampus and cortex, which is attenuated by rosiglitazone; this AND ASSOCIATED CHANGES IN BRAIN correlates with astrocytosis (Fig. 4). We also show a decrease in T2 relax- METABOLISM ANALYZED USING A 3-D VOXEL- ation time in hippocampus and cortex, which correlates with an increase in microglial activation (Fig. 5), and report that rosiglitazone-treatment ofaged rats increases hippocampal T2.
Anne-Sophie He´rard, Thierry Sylvie Cornet,Jessica LebenbergPierre-Etienne Chabrier, Philippe Marc 1CEA-MIRCen-CNRS URA 2210, Fontenay-Aux-Roses,France; 2SCRAS-IHB, Les Ulis, France. Contact e-mail: anne-sophie.
[email protected] Background: APPswe/PS1dE9 is a mouse model of Alzheimer's diseasethat starts to develop amyloid plaques by the age of 4 months. This studyevaluated early alterations of spatial memory and brain glucose metabolismin this mouse strain. The latter biomarker is of great interest in translationalstudies, as it can be evaluated both in animals and humans. Methods:APPswe/PS1dE9-transgenic (Tg) and C57BL/6 J amyloid free control(WT) mice were studied at 4.5 months, i.e. at the very beginning of amy-loid deposition. Spatial memory was evaluated using the Morris watermaze (nTg ¼ 14; nWT ¼ 14). During the training (4 trials/day for 4days) the latency and distance to reach platform (PF) were evaluated.
For the memory retention test, the PF was removed and mice were allowedto navigate for 60 seconds. The time spent in the target quadrant, the dis-tance moved, the number of crossing into PF zone, and the swim speedwere evaluated (Ethovision videotracking system, Noldus). Glucose uptakewas quantified in awake mice (nTg ¼ 6; nWT ¼ 7) by [14C]-2-deoxyglu-cose autoradiography of the whole brain (20-mm serial sections). 3D auto-radiographic brain volumes were reconstructed using BrainRAT (freely IN VIVO AMYLOID PLAQUE DETECTION USING available software, http://www.brainvisa.info) and statistical analyses CONTRAST-ENHANCED MAGNETIC RESONANCE were performed without any a priory hypothesis using SPM5. Cerebral am- MICROSCOPY IN TRANSGENIC MICE yloid deposits were examined in the same animals (BAM10 immunostain-ing and Congo red). Results: APPswe/PS1dE9 mice displayed significant Alexandra PetietAnne Christopher spatial memory alterations that could be detected in training (increased dis- Diane Thomas Debeir, Thomas , Marc , tance and latencies to reach the PF) and retention sessions (reduced time 1Sanofi-Aventis R&D, Vitry-sur-Seine, France; 2CNRS URA 2210, Mircen, spent in the quadrant). Despite these alterations, SPM analysis of glucose Orsay, France; 3CEA, DSV, I2BM, Neurospin, Gif-sur-Yvette, France.
metabolism revealed no statistically significant hypometabolic voxels in Contact e-mail: [email protected] Tg as compared to WT animals. On the contrary, hypermetabolic voxels Background: Amyloid plaques have previously been identified in mouse were identified bilaterally. They were located in lateral olfactory tracts models of Alzheimer's disease (AD) using magnetic resonance micros- and in the somatosensory and motor parietal cortex (increases of 12.0%/ Alzheimer's Imaging Consortium IC-P: Poster Presentations 13.7% and 13.9%/13.0% for the left and right sides of these structures).
Background: Intracellular inclusions of pathological tau fibrils are hall- Conclusions: Although young Tg mice displayed spatial memory impair- mark lesions in Alzheimer's disease (AD) and associated tauopathies, ment, no obvious hypometabolic brain regions was detected. Strikingly, Tg and there has been a growing interest in the mechanistic links between fi- mice even present with discrete areas of hypermetabolism in the somato- brillar tau accumulation and neuronal deterioration. In-vivo visualization sensory and motor parietal cortex and in olfactory areas. The fine relation- of tau lesions would thus serve the preclinical and clinical needs for pur- ship between these behavioral and metabolic changes remains to be suing the molecular etiology of neurodegenerative disorders and evaluat- ing candidate disease-modifying therapies. This notion has led us todevelop imaging agents capable of capturing tau aggregates in a living ALTERATIONS OF BRAIN GLUCOSE mouse model of tauopathies. Methods: An array of fluorescent chemicals METABOLISM IN AGED APP/PS1 MICE: AN were screened by assaying their in-vitro binding to recombinant tau fibrils ORIGINAL VOXEL-BASED STATISTICAL and neuronal tau inclusions on brain sections from patients with diverse ANALYSIS USING BRAINRAT AND SPM tauopathies and mice transgenic for the pathogenic P301S mutant tau.
Anne-Sophie He´Albertine , Nicolas The selected compounds were intravenously injected into the tau trans- Benoıˆt Delatour, Philippe Hantraye, Marc Dhenain, Thierry Delzescaux, genics, and ex-vivo labelings of tau lesions with these agents in excised 1CEA-MIRCen-CNRS URA 2210, Fontenay-Aux-Roses, France; brain samples were microscopically assessed. Pulse-laser optical and pos- 2CEA-SHFJ-INSERM U803, Orsay, France; 3Universite´ Paris Sud- itron emission tomographic (PET) systems were then applied to in-vivo NAMC-CNRS UMR 8620, Orsay, France. Contact e-mail: anne-sophie.
detections of tau pathologies in the transgenic mice with near-infrared fluorescent and 11C-labeled compounds, respectively. The PET datawere also supplemented by in-vitro and ex-vivo autoradiographic analyses.
Background: Glucose brain metabolism is a widely used clinical bio- Results: Chemical properties of the compounds such as structural dimen- marker in Alzheimer's disease (AD), usually examined on 2D post mortem sions and hydrophilicities were associated with their affinities for tau in- autoradiographic data in AD animal models. We propose an innovative clusions in a wide range of tauopathies as well as transgenics. A class method to analyze these data in 3D without a priori anatomical informa- of chemicals sharing the common core structure enabled ex-vivo visualiza- tion, to derive brain metabolic activity maps using voxel-based approach tion of aggregates in the transgenic mice. One of these putative imaging in APP/PS1 mice. Results will be discussed relative to previous findings agents was suitable for the near-infrared optics, and was proven to bind in this field. Methods: Uptake of [14C]-2-deoxyglucose was measured in to tau aggregated in living mouse brains based on the intensity and life- adult awake APP/PS1 (64 6 1 weeks, n ¼ 4) and PS1 (65 6 2 weeks, time of its fluorescent signals. Two other compounds of the same group n ¼ 3) transgenic mice. Glucose uptake was evaluated by autoradiography were radiolabeled with 11C, and were demonstrated to allow both autora- on the right hemisphere while the left hemisphere was processed for Congo diographic and PET detections of tau lesions in the transgenics. Conclu- red staining. Data acquisition was performed with a digital camera (block- sions: The present neuroimaging approaches using mouse models of the face photographs) and a high resolution flatbed scanner (autoradiography, diseases provide insights into the structural basis of molecular interactions histology). Blockface, autoradiographic and histological post mortem vol- between tau fibrils and exogenous compounds, which would facilitate the umes were 3D-reconstructed using BrainRAT in-house software (freely development of diagnostic and therapeutic agents for AD and non-AD available, http://brainvisa.info) while statistical analysis was achieved us- ing SPM5. Results: We successfully combined BrainRAT (computerizedprocedures for acquisition and 3D reconstruction of anatomic and func- DIAGNOSTIC UTILITY OF PLATELET AMYLOID tional volumes) and SPM5 (voxel-wise statistical analysis) methodologies PRECURSOR PROTEIN RATIO, RED BLOOD CELLS to data sets mapping brain metabolic activity in a transgenic mouse model AND PLASMA BETA AMYLOID (Ab 1-42) LEVELS of AD. We were able to extract accurate parametric mapping of both hypo- IN LATE-ONSET ALZHEIMER'S DISEASE and hypermetabolic regions in the APP/PS1 animals relative to PS1 con- Ben B'joe Vasudevan DevanathaSenthil Kumar, trols. Decreased glucose uptake was observed within cortex (cingulate Jeyakumar 1Sri Ramachandra Medical College, Chennai, India; -36%, retrosplenial -26%, somatosensory -23%), striatum (-22%), thalamus 2Kamakshi Memorial Hospital, Chennai, India; 3Central Leather Research (-29%) and hippocampus (-25%). Increased glucose uptake was also de- Institute, Chennai, India; 4Stanford University, Stanford, CA, USA.
tected within other cortical areas (piriform þ22%, perirhinal þ19%), Contact e-mail: [email protected] amygdala (þ23%), dorsal endopiriform (þ34%) and accumbens (þ20%)nuclei, dentate gyrus (þ25%) and dorsal hippocampus (þ26%). Conclu- Background: Alzheimer's disease (AD) is a severe neurodegenerative dis- sions: We have demonstrated the ability to robustly and automatically re- ease with a characteristic progressive decline in cognitive functions and de- construct post mortem functional volumes. We also provided accurate mentia. It is believed that the majority of all AD patients are affected by the cerebral glucose uptake mapping in a murine AD model, in 3D, without sporadic form, caused by the combined effects of several risk factors. In- a priori hypotheses. We offer an efficient and standardized method to com- creasing evidence suggests that abnormal processing of amyloid precursor pare local changes in mice cerebral glucose utilization across ages, lines or protein (APP) may play an important role in the pathogenesis of AD. The drugs. Furthermore, our work demonstrates the possibility of using func- present study focused on finding reliable biochemical markers in peripheral tional brain imaging and dedicated software to help bridge the gap, in venous blood and their relation to AD. Methods: The biochemical markers, translational studies, between features of neurodegenerative diseases in hu- platelets APP ratio, red blood cells (RBC), and plasma beta amyloid (Ab man beings and animal models.Acknowledgements: Sanofi-Aventis for 1-42) were quantitated in 40 probable/possible sporadic AD patients and sharing the mouse strains.
60 non demented age matched healthy controls. Results: The presentstudy found a reduction in platelet APP ratio. The magnetitude of the IN VIVO OPTICAL AND PET DETECTIONS OF APP ratio reduction is proportional to the severity of the cognitive loss FIBRILLAR TAU LESIONS IN A MOUSE MODEL OF in AD. The mean plasma Ab1-42 levels were higher in AD compared to age matched healthy subjects. In erythrocytes the mean RBC Ab1-42 Masahiro Maruyama, Jun Bin Ji, Ming-Rong levels were found to be decreased in AD but there was substantial individ- Takashi Maiko Ono, Satoko John Q. Trojanows ual variability and overlap in plasma and RBC Ab1-42 levels between Virginia M.-Y. Lee., Toshimitsu Fukumura, Makoto , these groups. Conclusions: Since platelet APP ratio is decreased at differ- Tetsuya Suhara, 1National Institute of Radiological Sciences, Chiba, Japan; ent stages of AD and abnormal APP processing is related to the neuropath- 2University of Pennsylvania, Philadelphia, PA, USA.
ological changes in AD brain, the present study suggests that the APPr Contact e-mail: [email protected] may assist in the early diagnosis of AD in individuals at risk for the disease

Source: http://jessica.lebenberg.free.fr/conferences/Herard-Lebenberg_ICAD2009.pdf